Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Lenvatinib plus pembrolizumab was associated with significantly longer progression- free survival and overall survival than sunitinib

ILLUMIN

ATE-A

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Lumasiran reduced urinary oxalate excretion, the cause of progressive kidney failure in PH1. The majority of patients who received lumasiran had normal or near normal levels after 6 months of treatment.

MENTOR

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

Rituximab was noninferior to cyclosporine in inducing complete or partial remission

of proteinuria at 12 months and was superior in maintaining proteinuria remission

up to 24 months

Rituximab was superior

Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease

Using a genotype-driven approach, we identified a disorder that connects seemingly unrelated adult-onset inflammatory syndromes.

We named this disorder the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome